Cargando…
Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039811/ https://www.ncbi.nlm.nih.gov/pubmed/21157451 http://dx.doi.org/10.1038/sj.bjc.6606037 |
| _version_ | 1782198237302620160 |
|---|---|
| author | Molina-Garrido, M J Guillén-Ponce, C |
| author_facet | Molina-Garrido, M J Guillén-Ponce, C |
| author_sort | Molina-Garrido, M J |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-3039811 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2011 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-30398112012-01-04 Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’ Molina-Garrido, M J Guillén-Ponce, C Br J Cancer Letter to the Editor Nature Publishing Group 2011-01-04 2010-12-14 /pmc/articles/PMC3039811/ /pubmed/21157451 http://dx.doi.org/10.1038/sj.bjc.6606037 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Molina-Garrido, M J Guillén-Ponce, C Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’ |
| title | Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’ |
| title_full | Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’ |
| title_fullStr | Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’ |
| title_full_unstemmed | Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’ |
| title_short | Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’ |
| title_sort | comment on ‘capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’ |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039811/ https://www.ncbi.nlm.nih.gov/pubmed/21157451 http://dx.doi.org/10.1038/sj.bjc.6606037 |
| work_keys_str_mv | AT molinagarridomj commentoncapecitabineandbevacizumabasfirstlinetreatmentinelderlypatientswithmetastaticcolorectalcancer AT guillenponcec commentoncapecitabineandbevacizumabasfirstlinetreatmentinelderlypatientswithmetastaticcolorectalcancer |